Tuesday, February 05, 2013
GSK - ViiV Abandons Lersivirine - An Investigational NNRTI HIV Medication
Dear HIV Community Writer,
ViiV Healthcare has taken the decision to stop the development program investigating the non-nucleoside reverse transcriptase inhibitor (NNRTI), lersivirine. This is not due to any safety concerns regarding the compound. ViiV Healthcare’s goal is to support the best possible outcomes for people living with HIV, and to deliver new therapies that offer improvement over current options.
After much deliberation about how to proceed with lersivirine, it was determined that the compound would not provide an improvement over existing medicines in the NNRTI class, and that R&D resources for ViiV Healthcare should prioritize efforts to identify compounds that further HIV treatment.
We remain committed to exploring candidates that will advance HIV treatment and contribute to improving outcomes for people living with HIV.
Please don’t hesitate to reach out to me directly if you have any questions regarding this announcement.
Marc Meachem | Director, External Affairs
- ▼ February (3)
- ► 2012 (120)
- ► 2011 (107)
- ► 2010 (68)
- ► 2009 (26)
- ► 2008 (77)
- ► 2007 (48)
- ► 2006 (36)
PoWeR's web sites
- Aging with HIV
- All about options to correct HIV related facial lipoatrophy (wasting)
- Michael Mooney's web site on hormones, exercise, nutrition, supplements, etc
- Nelson's bio web site
- Nelson's books on Amazon
- Nelson's favorite health books and gadgets
- Nelson's non profit : PoWeR
- Nelson's web site for people with limited HIV treatments
- Testosterone: A Man's Guide
- Upcoming web site with compounded products
- Web site for Nelson's second book: Testosterone: A Man's Guide
- Web site on emerging issues of aging with HIV
Ask Nelson Questions via TheBody.com
Use this link and ask him anything related to this blog. Also, look at past answers that he has provided to people.
Recommended Free Magazine
Subscribe here to get it mailed for free: